Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Johnson & Johnson (JNJ) PT Raised to $185 at Goldman Sachs
July 17, 2025 6:07 AM EDTGoldman Sachs analyst Asad Haider raised the price target on Johnson & Johnson (NYSE: JNJ) to $185.00 (from $177.00) while maintaining a Buy rating.
The analyst comments "In a backdrop where we had that noted our investor conversations suggest sentiment shifting slightly more positive on the tactical setup for US pharma into 2Q earnings season (see: link), JNJ shares... More
